期刊
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
卷 18, 期 -, 页码 2237-2246出版社
ELSEVIER
DOI: 10.1016/j.csbj.2020.08.009
关键词
-
资金
- Swedish Research Council
- Swedish Cancer Society
- Karolinska Institutet
- Swedish Rheumatism Association
- King Gustaf V's 80-year fund
- Ake Wiberg Foundation
- Stiftelsen Professor Nanna Svartz Fond
- Jeansson Foundations
- Alex and Eva Wallstrom Foundation for scientific research and education
- Wenner-Gren Foundations
- Borje Dahlin fund
- China Scholarship Council
- Nanyang Technological University - Karolinska Institutet Joint Ph.D. Programme
- EU/EFPIA Innovative Medicines Initiative Joint Undertaking (ULTRADD grant) [115766]
- EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (RTCure grant) [777357]
Over the last decade Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) has been developed into a potent molecular biology tool used to rapidly modify genes or their expression in a multitude of ways. In parallel, CRISPR-based screening approaches have been developed as powerful discovery platforms for dissecting the genetic basis of cellular behavior, as well as for drug target discovery. CRISPR screens can be designed in numerous ways. Here, we give a brief background to CRISPR screens and discuss the pros and cons of different design approaches, including unbiased genome-wide screens that target all known genes, as well as hypothesis-driven custom screens in which selected subsets of genes are targeted (Fig. 1). We provide several suggestions for how a custom screen can be designed, which could broadly serve as inspiration for any experiment that includes candidate gene selection. Finally, we discuss how results from CRISPR screens could be translated into drug development, as well as future trends we foresee in the rapidly evolving CRISPR screen field. (C) 2020 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据